David Sher, Vice Chair of Clinical Operations and Quality, Medical Director of Radiation Oncology, Chief of Head and Neck Radiation Oncology Service at UTSW Medical Center, shared Shankar Siva’s, Radiation Oncologist at the Peter MacCallum Cancer Centre, post on X, adding:
“Absolutely incredible work by Shankar Siva and colleagues!
Wow. My question is how to engage our surgical and medical oncology trialist colleagues to test this paradigm versus primary surgery.
Is this going to end up like bladder cancer?”
Quoting Shankar Siva’s post:
“ESTRO26 – FASTRACKII final results, median F/U of 5 years.
Thank you patients, funders, investigators.
- 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
- 100% Cancer-Specific Survival
- Grade 3 AEs remain at 10%.”
Other articles featuring David Sher and Shankar Siva on OncoDaily.